<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04808804</url>
  </required_header>
  <id_info>
    <org_study_id>Neurodegeneration In DM</org_study_id>
    <nct_id>NCT04808804</nct_id>
  </id_info>
  <brief_title>Retinal Neurodegeneration In Type 2 Diabetes Mellitus Detected by Optical Coherence Tomography</brief_title>
  <official_title>Retinal Neurodegeneration In Patients With Type 2 Diabetes Mellitus Without Diabetic Retinopathy or With Mild Non Proliferative Diabetic Retinopathy Detected by Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of retinal neurodegeneration in patients with type 2 diabetes mellitus (DM2)&#xD;
      without diabetic retinopathy or with mild non proliferative diabetic retinopathy&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinal complications in diabetes mellitus (DM) patients were typically considered part of a&#xD;
      vascular process. However, recent studies suggest that ocular degeneration in DM might be&#xD;
      caused by 2 different conditions: vasculopathy and neuropathy . For some authors, neuropathy&#xD;
      observed in the retina of DM patients might be a part of an underlying polyneuropathy ; for&#xD;
      others, however, neuropathic changes might precede microvascular alterations .&#xD;
&#xD;
      Axons of retinal ganglion cells compose the retinal nerve fiber layer (RNFL) in the retina&#xD;
      and then form the optic nerve connecting the eyeball and brain. Retinal nerve fiber layer&#xD;
      (RNFL) loss is recognized as an important neurodegenerative sign in glaucoma. Thinning of the&#xD;
      RNFL has also been found in multiple sclerosis, Parkinson's disease and Alzheimer's disease,&#xD;
      indicating neurodegeneration of the retina. If RNFL thinning is significant in diabetic&#xD;
      patients with preclinical diabetic retinopathy, evaluation of peripapillary RNFL thickness&#xD;
      would be very important, because early detection and treatment of diabetic retinopathy is&#xD;
      critical to reduce the risk of blindness Optical coherence tomography (OCT) has been&#xD;
      introduced into clinical practice as the most noninvasive and objective method to visualize&#xD;
      the retina, showing an amount of detail that resembles histological specimens. Initially, OCT&#xD;
      was applied to detect complications of DR (edema macular or epiretinal membrane). Later on,&#xD;
      it allowed quantitative and qualitative measurements of retinal thickness and segmentation of&#xD;
      all intraretinal layers. OCT might detect early retinal neurodegenerative changes, and thus&#xD;
      help define which diabetic patients may be at risk to develop DR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>RNFL thickness</measure>
    <time_frame>Baseline</time_frame>
    <description>retinal nerve fiber layer (RNFL) will be evaluated</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Retinal Neuropathy</condition>
  <condition>Neurodegeneration</condition>
  <arm_group>
    <arm_group_label>DM</arm_group_label>
    <description>Patients With Type 2 Diabetes Mellitus without any signs of diabetic retinopathy or with mild non proliferative diabetic retinopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Optical Coherence Tomography (OCT)</intervention_name>
    <description>a noninvasive imaging technology used to obtain high resolution cross-sectional images of the retina</description>
    <arm_group_label>DM</arm_group_label>
    <arm_group_label>Healthy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        40 eyes of patients with DM2 and without any signs of diabetic retinopathy or with mild non&#xD;
        proliferative diabetic retinopathy and 40 eyes of healthy controls&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with confirmed type 2 DM diagnosis of at least 6 months&#xD;
&#xD;
          -  Best-corrected visual acuity (BCVA) of 6/12 or higher (using a Snellen chart) in each&#xD;
             eye&#xD;
&#xD;
          -  Intraocular pressure (by applanation) less than 21 mmHg.&#xD;
&#xD;
          -  Healthy controls had no record nor evidence of ocular or neurologic disease of any&#xD;
             kind; their BCVA is &gt; 6/9 based on the Snellen scale.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  presence or past history of moderate or severe non proliferative diabetic retinopathy&#xD;
             or proliferative diabetic retinopathy , confirmed by indirect funduscopy or&#xD;
             retinography images.&#xD;
&#xD;
          -  presence of significant refractive errors (≥5 diopters of spherical equivalent&#xD;
             refraction or 3 diopters of astigmatism)&#xD;
&#xD;
          -  intraocular pressure ≥21 mmHg&#xD;
&#xD;
          -  media opacifications&#xD;
&#xD;
          -  concomitant ocular diseases, including history of glaucoma or retinal pathology&#xD;
&#xD;
          -  systemic conditions that could affect the visual system, including neurodegenerative&#xD;
             disorders such as Parkinson's disease, multiple sclerosis, or dementia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emel Saad Tawadrous, MBBCh</last_name>
    <phone>+201284854021</phone>
    <email>emelsaad@ymail.com</email>
  </overall_contact>
  <reference>
    <citation>Santos AR, Ribeiro L, Bandello F, Lattanzio R, Egan C, Frydkjaer-Olsen U, García-Arumí J, Gibson J, Grauslund J, Harding SP, Lang GE, Massin P, Midena E, Scanlon P, Aldington SJ, Simão S, Schwartz C, Ponsati B, Porta M, Costa MÂ, Hernández C, Cunha-Vaz J, Simó R; European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Functional and Structural Findings of Neurodegeneration in Early Stages of Diabetic Retinopathy: Cross-sectional Analyses of Baseline Data of the EUROCONDOR Project. Diabetes. 2017 Sep;66(9):2503-2510. doi: 10.2337/db16-1453. Epub 2017 Jun 29.</citation>
    <PMID>28663190</PMID>
  </reference>
  <reference>
    <citation>Shahidi AM, Sampson GP, Pritchard N, Edwards K, Vagenas D, Russell AW, Malik RA, Efron N. Retinal nerve fibre layer thinning associated with diabetic peripheral neuropathy. Diabet Med. 2012 Jul;29(7):e106-11. doi: 10.1111/j.1464-5491.2012.03588.x.</citation>
    <PMID>22269030</PMID>
  </reference>
  <reference>
    <citation>Salvi L, Plateroti P, Balducci S, Bollanti L, Conti FG, Vitale M, Recupero SM, Enrici MM, Fenicia V, Pugliese G. Abnormalities of retinal ganglion cell complex at optical coherence tomography in patients with type 2 diabetes: a sign of diabetic polyneuropathy, not retinopathy. J Diabetes Complications. 2016 Apr;30(3):469-76. doi: 10.1016/j.jdiacomp.2015.12.025. Epub 2015 Dec 30.</citation>
    <PMID>26809902</PMID>
  </reference>
  <reference>
    <citation>Simó R, Hernández C; European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives. Trends Endocrinol Metab. 2014 Jan;25(1):23-33. doi: 10.1016/j.tem.2013.09.005. Epub 2013 Nov 1. Review.</citation>
    <PMID>24183659</PMID>
  </reference>
  <reference>
    <citation>Zangwill LM, Bowd C. Retinal nerve fiber layer analysis in the diagnosis of glaucoma. Curr Opin Ophthalmol. 2006 Apr;17(2):120-31. Review.</citation>
    <PMID>16552246</PMID>
  </reference>
  <reference>
    <citation>Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A, Calabresi PA, Polman C. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2010 Sep;9(9):921-32. doi: 10.1016/S1474-4422(10)70168-X. Review. Erratum in: Lancet Neurol. 2010 Nov;9(11):1045.</citation>
    <PMID>20723847</PMID>
  </reference>
  <reference>
    <citation>Satue M, Garcia-Martin E, Fuertes I, Otin S, Alarcia R, Herrero R, Bambo MP, Pablo LE, Fernandez FJ. Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinson's disease patients. Eye (Lond). 2013 Apr;27(4):507-14. doi: 10.1038/eye.2013.4. Epub 2013 Feb 22.</citation>
    <PMID>23429414</PMID>
  </reference>
  <reference>
    <citation>Marziani E, Pomati S, Ramolfo P, Cigada M, Giani A, Mariani C, Staurenghi G. Evaluation of retinal nerve fiber layer and ganglion cell layer thickness in Alzheimer's disease using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2013 Sep 5;54(9):5953-8. doi: 10.1167/iovs.13-12046.</citation>
    <PMID>23920375</PMID>
  </reference>
  <reference>
    <citation>Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985 Dec;103(12):1796-806.</citation>
    <PMID>2866759</PMID>
  </reference>
  <reference>
    <citation>van Dijk HW, Verbraak FD, Stehouwer M, Kok PH, Garvin MK, Sonka M, DeVries JH, Schlingemann RO, Abràmoff MD. Association of visual function and ganglion cell layer thickness in patients with diabetes mellitus type 1 and no or minimal diabetic retinopathy. Vision Res. 2011 Jan 28;51(2):224-8. doi: 10.1016/j.visres.2010.08.024. Epub 2010 Aug 27.</citation>
    <PMID>20801146</PMID>
  </reference>
  <reference>
    <citation>Fischer MD, Huber G, Beck SC, Tanimoto N, Muehlfriedel R, Fahl E, Grimm C, Wenzel A, Remé CE, van de Pavert SA, Wijnholds J, Pacal M, Bremner R, Seeliger MW. Noninvasive, in vivo assessment of mouse retinal structure using optical coherence tomography. PLoS One. 2009 Oct 19;4(10):e7507. doi: 10.1371/journal.pone.0007507.</citation>
    <PMID>19838301</PMID>
  </reference>
  <reference>
    <citation>Ceklic L, Maár N, Neubauer AS. Optical coherence tomography fast versus regular macular thickness mapping in diabetic retinopathy. Ophthalmic Res. 2008;40(5):235-40. doi: 10.1159/000127830. Epub 2008 Apr 25.</citation>
    <PMID>18437033</PMID>
  </reference>
  <reference>
    <citation>Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT; Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003 Sep;110(9):1677-82. Review.</citation>
    <PMID>13129861</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 18, 2021</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Emel Saad Tawadrous</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Nerve Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

